U.S., Feb. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07380984) titled 'PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL' on Jan. 24.
Brief Summary: Natural killer/T-cell lymphoma (nasal type) is a mature T/NK-cell lymphoma closely associated with Epstein-Barr virus (EBV), with a high prevalence among populations in Asia and South America. It primarily occurs at extranodal sites, including the nasal/paranasal regions, skin, gastrointestinal tract, and other organs. This study focuses on previously untreated patients with early-stage NKTCL (nasal type), exploring a response-adapted comprehensive therapeutic strategy that combines PD-1 monoclonal antibody-based stratified targeted thera...